HLN 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2024

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

EXHIBIT INDEX

99.1

Divestment of the nicotine replacement therapy business outside of the US to Dr. Reddy's completed

30 September 2024: Haleon plc ("Haleon") (LSE/NYSE: HLN) today announces that it has completed the divestment of its nicotine replacement therapy ("NRT") business outside of the US.

On 26 June 2024, Haleon announced that it had entered into an agreement to sell its NRT business outside of the US to Dr. Reddy's Laboratories SA ("Dr. Reddy's"), a wholly owned subsidiary of Dr. Reddy's Laboratories Limited for total consideration of up to £500m (with additional proceeds from the transfer of inventory), which comprises an upfront payment of £458m and further deferred, performance-based consideration of up to £42m payable during 2025 and H1 2026.

Amanda Mellor

Company Secretary

Enquiries

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands

• such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

For more information please visit www.haleon.com

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.